Cargando…

CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies

Most hematological malignancies are characterized by overexpression of certain cancer promoting genes, such as MYC, MCL1 and cyclin D1. Preclinical studies in animal models have shown that CDK9 inhibitors supress the transcription of these anti-apoptotic and pro-survival proteins, and suggest their...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morillo, Daniel, Vega, Gala, Moreno, Victor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2023
Materias:	Research Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408673/ https://www.ncbi.nlm.nih.gov/pubmed/37552223 http://dx.doi.org/10.18632/oncotarget.28473

Ejemplares similares

Immune-based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies
por: Einsele, Hermann, et al.
Publicado: (2020)

Chimeric antigen T cell receptor treatment in hematological malignancies
por: Ali, Natasha
Publicado: (2019)

Genomic Stratification of Hematological Malignancies
por: Robbe, Pauline, et al.
Publicado: (2023)

The promise of immunotherapy in genitourinary malignancies
por: Zhang, Tian, et al.
Publicado: (2018)

Cellular immunotherapy as a beacon of hope for hematological malignancies
por: Lee, Hyun-Ju, et al.
Publicado: (2015)

Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies
por: Constantinescu, Catalin, et al.
Publicado: (2020)

CDK9 and H2B Monoubiquitination: A Well-Choreographed Dance
por: Johnsen, Steven A.
Publicado: (2012)

A multifaceted approach targeting NK cells for better treatment of cancer: focus on hematological malignancies
por: Kim, Hun Sik
Publicado: (2015)

The EHA Research Roadmap: Immune-based Therapies for Hematological Malignancies
por: Einsele, Hermann, et al.
Publicado: (2021)

Application of the CDK9 inhibitor FIT-039 for the treatment of KSHV-associated malignancy
por: Sakamoto, Tetsunori, et al.
Publicado: (2023)

Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?
por: Lelliott, Emily J., et al.
Publicado: (2022)

Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer
por: Tanguy, Marie-Laure, et al.
Publicado: (2018)

Combined BRD4 and CDK9 inhibition as a new therapeutic approach in malignant rhabdoid tumors
por: Moreno, Natalia, et al.
Publicado: (2017)

ASH Registry Offers Insights on COVID‐19 in Patients with Hematologic Malignancies
Publicado: (2020)

Acetylcholinesterase inhibitor modifications: a promising strategy to delay the progression of Alzheimer's disease
por: Bhattacharya, Soumee, et al.
Publicado: (2015)

Checkpoint inhibitors in hematological malignancies
por: Ok, Chi Young, et al.
Publicado: (2017)

“Partner”, “Caregiver”, or “Co-Survivor”—Might the Label We Give the Partners of Cancer Patients Affect the Health Outcome of the Patients and Their Partners?
por: McGillivray, Hannah M. K., et al.
Publicado: (2021)

Is CDK9 a promising target for both primary and metastatic osteosarcoma?
por: Qin, Jiang-Jiang
Publicado: (2019)

Mucositis and Infection in Hematology Patients
por: Blijlevens, Nicole M. A., et al.
Publicado: (2023)

Quantitative model of eukaryotic Cdk control through the Forkhead CONTROLLER
por: Barberis, Matteo
Publicado: (2021)

Differentiation therapy: a promising strategy for cancer treatment
por: Yan, Min, et al.
Publicado: (2016)

CAR-T cell therapy for hematological malignancies: History, status and promise
por: Wang, Chao, et al.
Publicado: (2023)

CDK9 inhibitors in acute myeloid leukemia
por: Boffo, Silvia, et al.
Publicado: (2018)

Cyclin-Dependent Kinase Inhibitors in Hematological Malignancies—Current Understanding, (Pre-)Clinical Application and Promising Approaches
por: Richter, Anna, et al.
Publicado: (2021)

Publishing Protocols for Partnered Research
por: Hysong, Sylvia J., et al.
Publicado: (2014)

Membrane resealing as a promising strategy for early treatment of neurotrauma
por: Jin, Xiaoming
Publicado: (2014)

CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
por: Marofi, Faroogh, et al.
Publicado: (2021)

Biologicals and Biosimilars in Hematology: The Case of Rituximab
por: Vulto, Arnold G.
Publicado: (2019)

The EHA Research Roadmap: Infections in Hematology
por: Cordonnier, Catherine, et al.
Publicado: (2021)

Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020
por: Du, Jianhua, et al.
Publicado: (2021)

Relay strategies combined with axon regeneration: a promising approach to restore spinal cord injury
por: Hou, Shaoping
Publicado: (2014)

Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity
por: Chen, Zhenghu, et al.
Publicado: (2016)

Fecal Microbiota Transplantation: An Ambiguous Translational Pathway for a Promising Treatment
por: Joseph, Josiane, et al.
Publicado: (2019)

Environmental enrichment as a promising strategy for aiding multiple sclerosis treatment
por: Silva, Berenice Anabel, et al.
Publicado: (2020)

Pharma partnering: other people’s science
por: Hofmann, Christian
Publicado: (2017)

Coronavirus disease-19 and its hematological manifestations
por: Kim, Hye-Ran, et al.
Publicado: (2020)

Mechanistic models for hematological toxicities: Small is beautiful
por: Deyme, Laure, et al.
Publicado: (2021)

Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
por: Federico, Mario, et al.
Publicado: (2011)

Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies
por: Imai, Yoichi, et al.
Publicado: (2016)

TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies
por: Jin, Shenhe, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5ajofmdsi4k9lmmaqgo5btnbas